Kura Oncology (KURA) Competitors

Zymeworks (NYSE:ZYME) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Does the media refer more to ZYME or KURA?

In the previous week, Kura Oncology had 7 more articles in the media than Zymeworks. MarketBeat recorded 14 mentions for Kura Oncology and 7 mentions for Zymeworks. Kura Oncology's average media sentiment score of 0.77 beat Zymeworks' score of 0.42 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kura Oncology	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ZYME or KURA more profitable?

Kura Oncology has a net margin of 0.00% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-182.75%	-23.00%	-18.04%
Kura Oncology	N/A	-44.09%	-39.57%

Do analysts prefer ZYME or KURA?

Zymeworks presently has a consensus price target of $19.00, suggesting a potential upside of 23.46%. Kura Oncology has a consensus price target of $28.83, suggesting a potential upside of 81.11%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Kura Oncology is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83
Kura Oncology	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has more risk and volatility, ZYME or KURA?

Zymeworks has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of ZYME or KURA?

92.9% of Zymeworks shares are owned by institutional investors. 1.9% of Zymeworks shares are owned by company insiders. Comparatively, 5.5% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has better earnings and valuation, ZYME or KURA?

Zymeworks has higher revenue and earnings than Kura Oncology. Zymeworks is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$76.01M	13.95	-$118.67M	-$1.50	-10.26
Kura Oncology	N/A	N/A	-$152.63M	-$2.36	-6.75

Does the MarketBeat Community prefer ZYME or KURA?

Kura Oncology received 127 more outperform votes than Zymeworks when rated by MarketBeat users. Likewise, 69.32% of users gave Kura Oncology an outperform vote while only 67.99% of users gave Zymeworks an outperform vote.

Company	Underperform	Outperform
Zymeworks	Outperform Votes 291 67.99%	Underperform Votes 137 32.01%
Kura Oncology	Outperform Votes 418 69.32%	Underperform Votes 185 30.68%

Summary

Kura Oncology beats Zymeworks on 10 of the 17 factors compared between the two stocks.